Medtronic plc
MDTHealthcareNASDAQMedical Devices · Last scanned Jul 17, 2026
Scan Results
Daily timeframeMedtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients in the United States, Ireland, and internationally. With a market capitalization of $106.50B, it sits in large-cap territory. It operates through three segments: The Cardiovascular Portfolio, Neuroscience Portfolio, and Medical Surgical Portfolio.
Market Cap
$106.50B
Beta
0.58
P/E (TTM)
22.43
P/E (Fwd)
12.99
EPS (TTM)
$3.71
EPS (Fwd)
$6.41
ROE
9.8%
ROA
4.9%
Cash
$9.22B
Total Debt
$29.15B
Free CF
$4.63B
52W Change
-7.1%
Annual Financials
Cash vs Debt
The company holds $9.22B in cash, though total debt stands at $29.15B. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. Free cash flow comes in at $4.63B, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. Return on equity stands at 9.8%, which is decent for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. ROA of 4.9% is on the lower side, which is common in asset-heavy industries. Revenue has been uneven over recent years, ranging from $31.23B to $36.36B.
The relatively low beta of 0.58 suggests MDT is a less volatile holding compared to the broader index. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Medtronic plc's trajectory.